Drug intelligence / Profile preview

Paratoulene phosphate

Development stage: Unknown
Modality: Small Molecules

Overview

Paratoulene phosphate is an experimental small molecule compound classified as a dipeptide derivative. It has not been approved for use in the United States or other regions and currently has no known clinical indications. The chemical formula is C30H34N3O7P, with a molecular weight of approximately 579.58 g/mol. There is no detailed information available regarding its mechanism of action, pharmacological activity, or therapeutic applications[1].

Other names: Paratoulene phosphate

Targets

SRC (Proto-oncogene tyrosine-protein kinase Src)

Beyond the preview

Go deeper on Paratoulene phosphate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Paratoulene phosphate.

Explore the full profile